ROCHE REQUESTS RE-EXAMINATION OF CHMP OPINION ON TARCEVA IN PANCREATIC CANCER AT THE EUROPEAN MEDICINES AGENCY

Roche announced that it has requested a re-examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment of pancreatic cancer following the recent negative opinion from the European Committee for Medicinal Products for Human Use (CHMP). BioSpace (http://www.biospace.com/news_story.aspx?StoryID=28941&full=1)